Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis

ConclusionsThe regimens of 12 weeks of EBR/GZR without RBV, and 16 weeks of EBR/GZR plus RBV, were efficacious in HCV GT4‐infected treatment‐naïve and treatment‐experienced participants, respectively. Baseline NS5A resistance‐associated substitutions did not impact the efficacy of EBR/GZR in GT4‐infected participants.This article is protected by copyright. All rights reserved.

Source: Liver International - February 20, 2018 Category: Gastroenterology Authors: Tarik Asselah, Hendrik Reesink, Jan Gerstoft, Victor de Ledinghen, Paul J. Pockros, Michael Robertson, Peggy Hwang, Ernest Asante ‐Appiah, Janice Wahl, Bach‐Yen Nguyen, Eliav Barr, Rohit Talwani, Lawrence Serfaty Tags: Original Article Source Type: research